• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by SciSparc Ltd.

    7/31/25 4:05:16 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRC alert in real time by email
    6-K 1 ea0250762-6k_scisparc.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    under the Securities Exchange Act of 1934

     

    For the month of July 2025 (Report No. 3)

     

    Commission File Number: 001-38041

     

    SCISPARC LTD.

    (Translation of registrant’s name into English)

     

    20 Raul Wallenberg Street, Tower A,

    Tel Aviv 6971916 Israel

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒         Form 40-F ☐

     

     

     

     

     

     

    CONTENTS

     

    Press Releases

     

    On July 30, 2025, SciSparc Ltd. (the “Company”) issued: (i) a press release titled “SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease,” a copy of which is furnished herewith as Exhibit 99.1 and is incorporated by reference herein; and (ii) a press release titled “SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC,” a copy of which is furnished herewith as Exhibit 99.2 and is incorporated by reference herein.

     

    Additional Information and Where You Can Find It

     

    In connection with the proposed transactions between the Company and AutoMax Motors Ltd. (“AutoMax”), the Company has filed a registration statement, which has been declared effective by the SEC, and a proxy statement/prospectus with the Securities and Exchange Commission (the “SEC”). This communication is not a substitute for the registration statement or the proxy statement/prospectus or any other documents that the Company may file with the SEC or send to its shareholders in connection with the proposed transactions. Before making any voting decision, investors and securityholders are urged to read the registration statement or the proxy statement/prospectus, as applicable, and all other relevant documents filed or furnished or that will be filed with or furnished to the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction and related matters.

     

    You may obtain free copies of the registration statement, the proxy statement/prospectus and all other documents filed or that will be filed with the SEC regarding the proposed transaction at the website maintained by the SEC at www.sec.gov. The proxy statement/prospectus is available free of charge on the Company’s website at https://investor.scisparc.com/, by contacting the Company’s Investor Relations at [email protected] or by phone at +972-3-6167055.

     

    Participants in Solicitation

     

    The Company, AutoMax and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of the Company’s Ordinary Shares in connection with the proposed transaction. Information about the Company’s directors and executive officers is set forth in the Company’s Annual Report on Form 20-F, for the year ended December 31, 2024, filed with the SEC on April 24, 2025. Other information regarding the interests of such individuals, as well as information regarding AutoMax’s directors and executive officers and other persons who may be deemed participants in the proposed transaction, is set forth in the proxy statement/prospectus. You may obtain free copies of these documents as described in the preceding paragraph.

     

    Non-Solicitation

     

    This Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) will not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

     

    Third Amendment to LOI with Miza III Ventures Inc

     

    On July 31, 2025, the Company entered into a third amendment (the “Amendment”) to the non-binding letter of intent (the “LOI”), as amended on December 16, 2024 and on March 28 2025, with Miza III Ventures Inc. (“Miza”). According to the Amendment, the deadline to enter into definitive agreements was extended from June 30, 2025, to October 15, 2025, provided that such date may be further extended by mutual written agreement of the parties, and to close the proposed transaction by no later than October 31, 2025, which was extended from July 31, 2025. All other material terms of the LOI remain unchanged and the parties continue to work diligently towards the completion of the proposed transaction.

     

    Forward-Looking Statements

     

    This Form 6-K contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward-looking statements when discussing that the deadline to enter into definitive agreements may be further extended by mutual written agreement of the parties and the timing of the closing of the proposed transaction. Since such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this Form 6-K. The forward-looking statements contained or implied in this Form 6-K are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the SEC on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

     

    Incorporation by Reference

     

    This Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-233417, 333-248670 and 333-255408) and on Form S-8 (File Nos. 333-278437, 333-225773 and 333-286791) filed with the SEC to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    1

     

     

    EXHIBIT INDEX

     

    Exhibit No.    
    99.1   Press release issued by SciSparc Ltd. titled “SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease.”
    99.2   Press release issued by SciSparc Ltd. titled “SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC.”

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      SciSparc Ltd.
         
    Date: July 31, 2025 By: /s/ Oz Adler
      Name: Oz Adler
      Title: Chief Executive Officer and Chief Financial Officer

     

    3

     

    Get the next $SPRC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SPRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SPRC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

    Vancouver, Canada, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd. (NASDAQ:SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company developing therapies for central nervous system disorders. The patent application published under the European Patent Office covers an innovative combinatio

    8/7/25 7:32:00 AM ET
    $CMND
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

    TEL AVIV, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind") has led to the publication of an international patent application under the Patent Cooperation Treaty (PCT). The patent application published under the European Patent Office covers an innovative combination therapy of Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) for the treatment

    8/7/25 7:32:00 AM ET
    $CMND
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

    TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announces additional progress in connection with the proposed merger with AutoMax Motors Ltd., a leading vehicles importer and the exclusive importer of Anhui Jianghuai Automobile Group Corp., Ltd.-manufactured electric vehicles in Israel ("AutoMax").  As previously disclosed, in April 2024, SciSparc and AutoMax entered into a merger agreement, as amended, under which, SciSparc will acquire 100% of the share capital of AutoMax by way of a r

    7/30/25 4:34:00 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRC
    SEC Filings

    View All

    SEC Form 6-K filed by SciSparc Ltd.

    6-K - SciSparc Ltd. (0001611746) (Filer)

    8/8/25 6:05:29 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by SciSparc Ltd.

    6-K - SciSparc Ltd. (0001611746) (Filer)

    7/31/25 4:05:16 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by SciSparc Ltd.

    EFFECT - SciSparc Ltd. (0001611746) (Filer)

    7/31/25 12:15:12 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRC
    Financials

    Live finance-specific insights

    View All

    SciSparc Adopts Limited Duration Shareholder Rights Plan

    TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its Board of Directors (the "Board") has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately. "Today we announced exciting positive results from our weight loss and metabolic disorder program with our proprietary psychedelic-based treatment," said Oz Adler, SciSparc's Chief Executive Officer. "Unfortunately, SciSparc, like many other clinical-stag

    11/28/23 8:55:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel

    SciSparc seeks to scale up revenues and will consider transferring its pharmaceutical activities to a separate legal entity and exploring the possibility of dividend distribution TEL AVIV, Israel, Nov. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the signing of a non-binding letter of intent to merge with a leading vehicle importer company in Israel (the "Target Company"). This merger (the "Merger) is expected to be consummated by means of a reverse triangular merger, pursua

    11/22/23 7:42:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split

    Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announces today that its previously announced reverse share split of its issued and outstanding ordinary shares, no par value at a ratio of 1-for-26, is expected to be implemented after market close today. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at

    9/27/23 7:58:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRC
    Leadership Updates

    Live Leadership Updates

    View All

    SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP

    As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities TEL AVIV, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that as part of its restructuring plans to unlock value for shareholders, it has appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, to structure business strategies and facilitate identifying new business opportunities. Mr. Baranes is a business strategy expert with a

    5/30/23 8:40:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins

    JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the appointment of Prof. Ciro Leonardo Pierri as special advisor for MitoCareX Bio Ltd. ("MitoCareX Bio"), SciSparc's recently established joint venture ("JV") for the discovery and development of potential drugs for cancers, infectious diseases and other life-threatening conditions. Prof. Pierri is a biochemist and serves as an associate professor at the U

    6/15/22 8:30:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain

    Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroed

    3/30/22 8:30:00 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SciSparc Ltd.

    SC 13G - SciSparc Ltd. (0001611746) (Subject)

    3/6/24 5:02:18 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SciSparc Ltd.

    SC 13G - SciSparc Ltd. (0001611746) (Filed by)

    12/13/22 6:22:30 AM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by SciSparc Ltd. (Amendment)

    SC 13G/A - SciSparc Ltd. (0001611746) (Subject)

    5/9/22 4:08:30 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care